Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The TriCinch System™ is intended for percutaneous treatment of tricuspid regurgitation.

It is a percutaneous catheter-based device designed for tricuspid valve repair in order to decrease effective cross-sectional area and relieve symptoms in patients with tricuspid valve regurgitation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System

NCT03294200

Tricuspid Regurgitation

TERMINATED NA

Early Feasibility Study of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System

NCT03632967

Functional Tricuspid Regurgitation Heart Valve Diseases Tricuspid Valve Insufficiency

TERMINATED NA

TRICUS STUDY - Safety and Efficacy of the TricValve® Device

NCT03723239

Severe Tricuspid Regurgitation

COMPLETED NA

TRICUS STUDY Euro - Safety and Efficacy of the TricValve® Device

NCT04141137

Severe Tricuspid Regurgitation

COMPLETED NA

A First in Human Study for the Versa Device for Tricuspid Regurgitation

NCT06368401

Tricuspid Regurgitation

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Implantation Procedure: Unlike the standard open chest, arrested heart approach, the 4TECH TriCinch System™ provides a percutaneous solution for tricuspid valve regurgitation treatment: this procedure is performed through deep sedation, while the heart is beating, without the need for respiratory assistance.

The TriCinch System™ consists of a Delivery System that enables transcatheter placement of an implant that can be adjusted to correct Tricuspid valve regurgitation. The TriCinch Delivery System is inserted from the femoral vein to access the right atrium of the heart. At the end of the correction process, the TriCinch Delivery System and the venous introducer are removed and the procedure is concluded.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tricuspid Regurgitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Percutaneous treatment of TR by TriCinch

Percutaneous treatment of Tricuspid Regurgitation with TriCinch System

Group Type EXPERIMENTAL

TriCinch System

Intervention Type DEVICE

Percutaneous treatment of Tricuspid Regurgitation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TriCinch System

Percutaneous treatment of Tricuspid Regurgitation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Functional symptomatic tricuspid regurgitation (TR) 2+ to 4+ on a scale of 4+ (moderate to severe), with annular dilatation greater than 40mm.
* Signed informed consent form prior to any study-related procedure.
* Available and able to return to the study site for post-procedural follow-up examination
* Eighteen (18) years of age or older.

Exclusion Criteria

* Requirement for concomitant cardiac procedure (other than atrial fibrillation correction surgery, closure of PFO (Patent Foramen Ovale) or ASD (Atrial Septal Defect), or PTCA (percutaneous treatment of coronary artery) or CAD (coronary artery bypass surgery) from 1 to 3 months after or before other procedure.
* Presence of any known life threatening (non-cardiac major or progressive disease), non-cardiac disease that will limit the subject's life expectancy to less than one year.
* Cerebro-vascular event within the past 6 months.
* History of mitral/tricuspid endocarditis within the last 12 months.
* Organic tricuspid disease.
* Contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately premeditated.
* Severe hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg, measurement done by sphygmomanometer with stethoscope, allow the patient to sit for at least 5 minutes before beginning BP measurements).
* Female patient is pregnant (urine HCG test result positive) or lactating.
* Known alcohol or drug abuser.
* Currently participating in the study of an investigational drug or device.
* At heart team's judgement, patient IVC dimension is not adequate for device implantation.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No